Aganepag, a potent Prostanoid EP2 receptor agonist, exhibits remarkable selectivity with an EC50 of 0.19 nM, demonstrating no activity at the EP4 receptor. Its applications are primarily in the fields of woundhealing, scar reduction, scar prevention, and the treatment and prevention of wrinkles.
CEP03 enhances EC EPC proliferation, tubelike formation, and wound-healing efficiency, leading to promote angiogenesis and significantly improve blood flow perfusion recovery in the ischemic hind limbs of mice.